TNGX Valuation

Tango Therapeutics Inc

Add to Watchlist

Advanced Chart

6.710

-0.11(-1.613%)1D

Overview
Forecast
Valuation
Earnings

TNGX Relative Valuation

TNGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TNGX is overvalued; if below, it's undervalued.

Historical Valuation

Tango Therapeutics Inc (TNGX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 17.26 is considered Undervalued compared with the five-year average of -5.61. The fair price of Tango Therapeutics Inc (TNGX) is between 11.73 to 19.46 according to relative valuation methord. Compared to the current price of 6.71 USD , Tango Therapeutics Inc is Undervalued By 42.77%.

Relative Value

Fair Zone

11.73-19.46

Current Price：6.71

42.77%

Undervalued

-5.88

Trailing

Forward

0.00

EV/EBITDA

Tango Therapeutics Inc. (TNGX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.37. The thresholds are as follows: Strongly Undervalued below -8.79, Undervalued between -8.79 and -5.58, Fairly Valued between 0.83 and -5.58, Overvalued between 0.83 and 4.04, and Strongly Overvalued above 4.04. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-4.18

EV/EBIT

Tango Therapeutics Inc. (TNGX) has a current EV/EBIT of -4.18. The 5-year average EV/EBIT is -2.52. The thresholds are as follows: Strongly Undervalued below -8.53, Undervalued between -8.53 and -5.52, Fairly Valued between 0.49 and -5.52, Overvalued between 0.49 and 3.50, and Strongly Overvalued above 3.50. The current Forward EV/EBIT of -4.18 falls within the Historic Trend Line -Fairly Valued range.

17.26

Tango Therapeutics Inc. (TNGX) has a current PS of 17.26. The 5-year average PS is 21.13. The thresholds are as follows: Strongly Undervalued below -3.73, Undervalued between -3.73 and 8.70, Fairly Valued between 33.56 and 8.70, Overvalued between 33.56 and 45.98, and Strongly Overvalued above 45.98. The current Forward PS of 17.26 falls within the Historic Trend Line -Fairly Valued range.

-4.69

P/OCF

Tango Therapeutics Inc. (TNGX) has a current P/OCF of -4.69. The 5-year average P/OCF is -2.85. The thresholds are as follows: Strongly Undervalued below -8.75, Undervalued between -8.75 and -5.80, Fairly Valued between 0.11 and -5.80, Overvalued between 0.11 and 3.06, and Strongly Overvalued above 3.06. The current Forward P/OCF of -4.69 falls within the Historic Trend Line -Fairly Valued range.

-4.63

P/FCF

Tango Therapeutics Inc. (TNGX) has a current P/FCF of -4.63. The 5-year average P/FCF is -1.99. The thresholds are as follows: Strongly Undervalued below -7.43, Undervalued between -7.43 and -4.71, Fairly Valued between 0.73 and -4.71, Overvalued between 0.73 and 3.44, and Strongly Overvalued above 3.44. The current Forward P/FCF of -4.63 falls within the Historic Trend Line -Fairly Valued range.

Tango Therapeutics Inc (TNGX) has a current Price-to-Book (P/B) ratio of 5.51. Compared to its 3-year average P/B ratio of 2.64 , the current P/B ratio is approximately 109.12% higher. Relative to its 5-year average P/B ratio of 1.88, the current P/B ratio is about 193.77% higher. Tango Therapeutics Inc (TNGX) has a Forward Free Cash Flow (FCF) yield of approximately -19.66%. Compared to its 3-year average FCF yield of -27.37%, the current FCF yield is approximately -28.17% lower. Relative to its 5-year average FCF yield of -22.81% , the current FCF yield is about -13.80% lower.

5.51

P/B

Median3y

2.64

Median5y

1.88

-19.66

FCF Yield

Median3y

-27.37

Median5y

-22.81

Competitors Valuation Multiple

The average P/S ratio for TNGX's competitors is 100.85, providing a benchmark for relative valuation. Tango Therapeutics Inc Corp (TNGX) exhibits a P/S ratio of 17.26, which is -82.89% above the industry average. Given its robust revenue growth of -83.99%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TNGX.O

Tango Therapeutics Inc

Nurix Therapeutics Inc

Dianthus Therapeutics Inc

Taysha Gene Therapies Inc

Anavex Life Sciences Corp

Loss

828.02M

Performance Decomposition

Market capitalization of TNGX decreased by 43.28% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -128.56 to -1.22K.

The secondary factor is the Revenue Growth, contributed -83.99%to the performance.

Overall, the performance of TNGX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-83.99%

19.88M → 3.18M

Revenue Growth

850.07%

-128.56 → -1.22K

Margin Expansion

-809.36%

0.72 → -5.08

P/E Change

-43.28%